Ryu Seunghyong, Cho Eun Young, Park Taesung, Oh Sohee, Jang Won-Seok, Kim Shin-Kyum, Lee Dongsoo, Hong Kyung Sue
Department of Psychiatry, Sungkyunkwan University School of Medicine, Samsung Medical Center, 50 Ilwon-Dong, Kangnam-Gu, Seoul 135-710, South Korea.
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):673-7. doi: 10.1016/j.pnpbp.2006.12.021. Epub 2007 Jan 12.
5-HT2C receptor gene is viewed as an important candidate gene in pharmacogenetic studies of antipsychotic drug-induced weight gain. However, inconsistent results have been obtained in different populations. We investigated the association between the -759C/T polymorphism of the 5-HT2C receptor gene with early phase (after 4 weeks of treatment) weight gain induced by antipsychotic treatment in Korean schizophrenia patients. The study subjects were eighty-four in-patients receiving monotherapy with one of six antipsychotic drugs. Patients with the variant allele (-759T) were found to be less likely to have substantial (> 5%) weight gain (Fisher's exact test, p=0.030), and this association (t=1.91, df=75, p=0.030) was supported by the repeated measures analysis after controlling for possible confounding effects, i.e., age, sex, baseline BMI, and the type of antipsychotic medicine administered. The variant allele also appeared to have a protective effect against weight gain in a subgroup of patients receiving risperidone. These results support the involvement of the -759C/T polymorphism of the 5-HT2C receptor gene in antipsychotics-induced weight gain in the Korean population.
5-羟色胺2C受体基因被视为抗精神病药物所致体重增加的药物遗传学研究中的一个重要候选基因。然而,在不同人群中得到的结果并不一致。我们调查了韩国精神分裂症患者中5-羟色胺2C受体基因-759C/T多态性与抗精神病药物治疗早期阶段(治疗4周后)体重增加之间的关联。研究对象为84名接受六种抗精神病药物之一单一疗法的住院患者。发现携带变异等位基因(-759T)的患者体重显著增加(>5%)的可能性较小(Fisher精确检验,p=0.030),在控制了可能的混杂效应,即年龄、性别、基线体重指数和所使用的抗精神病药物类型后,重复测量分析支持了这种关联(t=1.91,自由度=75,p=0.030)。在接受利培酮治疗的患者亚组中,变异等位基因似乎也对体重增加具有保护作用。这些结果支持5-羟色胺2C受体基因-759C/T多态性参与了韩国人群中抗精神病药物所致的体重增加。